Rethinking the Coronary Artery Calcium Score: From Plaque Burden to Vascular Terrain

By Dustin Strong, CHN, ACN

The Coronary Artery Calcium Score (CACS) is widely used as a non-invasive tool to assess cardiovascular risk by quantifying calcified plaque within the coronary arteries. Robust evidence supports its predictive value for future cardiovascular events, particularly when used alongside traditional risk factors (Greenland et al., 2018; Budoff et al., 2018).

However, while CACS is a valuable marker, its interpretation is often overly reductionist - framed primarily as a direct measure of disease burden rather than a reflection of underlying vascular processes.

Calcification as a Marker of Vascular Adaptation

Coronary calcification is increasingly understood not as the initiating event in atherosclerosis, but as part of a later-stage remodeling process. Histopathological and imaging studies suggest that calcification may represent a stabilizing response to chronic inflammation within the arterial wall, particularly in previously lipid-rich plaques (Virmani et al., 2000; Ehara et al., 2004).

In this context, CACS reflects:

• Cumulative exposure to vascular injury

• Chronic inflammatory signaling

• Ongoing cycles of damage and repair

Importantly, it does not reliably distinguish between:

• Active vs. quiescent disease

• Stable vs. vulnerable plaque

• Regional differences in vascular function

This distinction is clinically significant when interpreting both baseline scores and longitudinal changes.

Limitations of a Calcification-Centered Model

Interventions aimed at modifying CACS have historically focused on:

• Lipid lowering

• Mineral metabolism

• Anti-inflammatory strategies

While these approaches may influence disease progression, changes in calcium score are often heterogeneous and non-linear. In some cases, progression of calcification has been observed despite reductions in cardiovascular events - suggesting that increasing calcification may, paradoxically, reflect plaque stabilization rather than worsening risk (Puri et al., 2015).

Conversely, reductions in CACS, while occasionally reported in smaller or non-traditional interventions, are not yet consistently reproducible across large-scale studies and should be interpreted cautiously.

The Microvascular Dimension: An Underrecognized Driver

A growing body of evidence highlights the central role of the coronary microcirculation in cardiovascular health. It is estimated that the majority of myocardial blood flow is regulated at the level of small arterioles and capillaries, which are critical for oxygen delivery, endothelial signaling, and metabolic regulation (Taqueti & Di Carli, 2018).

Microvascular dysfunction has been associated with:

• Persistent ischemia in the absence of obstructive coronary disease

• Endothelial dysregulation

• Ongoing inflammatory signaling

• Impaired tissue-level perfusion

Importantly, microvascular impairment may coexist with, or persist independently of, macrovascular plaque burden. This provides a plausible explanation for the regional variability sometimes observed in serial CACS measurements, where certain areas improve while others remain unchanged.

Toward a Systems-Based Framework

These insights support a shift from a calcification-centric model to a systems-based approach to cardiovascular health, integrating multiple physiological domains:

1. Inflammatory and immune regulation

2. Metabolic function and insulin sensitivity

3. Mineral balance and vascular remodeling

4. Lipid transport and plaque dynamics

5. Microvascular integrity and perfusion

Within this framework, CACS is best understood as a contextual biomarker - one that reflects aspects of long-term vascular history but does not fully capture current physiological state.

Integrative Considerations for Vascular Support

Interventions that support vascular health may reasonably extend beyond traditional lipid-centric strategies to include:

• Nutritional approaches targeting metabolic and inflammatory balance

• Nutrients supporting connective tissue and endothelial function (e.g., vitamin C, flavonoids)

• Compounds associated with microvascular support and capillary integrity

Botanical agents such as Ginkgo biloba, Centella asiatica, and Vaccinium myrtillus have demonstrated effects on microcirculatory dynamics, endothelial function, and oxidative stress in preclinical and clinical contexts (Clifford et al., 2012; Belcaro et al., 2011). While not specific treatments for coronary calcification, they may contribute to supporting the vascular environment in which repair and regulation occur.

Clinical Implications

When evaluating CACS over time, clinicians may consider:

• The possibility of discordant regional changes

• The role of microvascular function in persistent disease activity

• The importance of adjunctive biomarkers (e.g., hs-CRP, insulin resistance, endothelial markers)

Rather than focusing solely on modifying the calcium score, the clinical objective shifts toward:

Optimizing the internal environment that governs vascular health and resilience.

Conclusion

The Coronary Artery Calcium Score remains a valuable tool in cardiovascular risk assessment. However, its greatest utility may lie not in isolation, but as part of a broader, integrative understanding of vascular biology.

As the field evolves, so too must our interpretation:

CACS is not simply a measure of plaque.It is a signal—one that reflects the history of vascular stress, adaptation, and repair.

And it invites a deeper question:

What is the current state of the system that produced it?

Selected References

• Greenland P, et al. (2018). 2018 ACC/AHA Guideline on the Management of Blood Cholesterol.

• Budoff MJ, et al. (2018). Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease events.

• Virmani R, et al. (2000). Lessons from sudden coronary death: a comprehensive morphological classification scheme.

• Ehara S, et al. (2004). Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction.

• Puri R, et al. (2015). Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.

• Taqueti VR, Di Carli MF. (2018). Coronary microvascular disease pathogenesis and clinical implications.

• Clifford T, et al. (2012). The effects of flavonoids on cardiovascular health.

• Belcaro G, et al. (2011). Pycnogenol and microcirculation: clinical studies.